Maven Biotechnologies, a Pasadena, CA-based biotechnology company, has been awarded $1.96m by the National Institute for Allergy and Infectious Disease (NIAID), part of the NIH.
The grant, which was awarded through the federal stimulus package initiative for Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN), will be used to support the commercialization of the company’s LFIRE™ imaging technology for label-free protein microarrays and cell-based assays.
The platform addresses applications in biomedical research, drug discovery, immunodiagnostics, biodefense, biological manufacturing and point-of-care.
Maven holds 14 granted US and international patents.
The initial instrument will be a desktop microplate reader, with a set of ‘alpha’ evaluation units expected to be completed in the first quarter of 2011 and made available for use by key academic collaborators and strategic industry partners.
The company’s founder and CEO William Rassman M.D. said that the grant will enable Maven to start commercializing the product and “will be the forerunner of other funding events”.